TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2791714
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g single pre‐operative dose, continued daily for 5 days in perforated appendicitis)
Study: 196421
Drug: LUPIDON H
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUPIDON H or LUPIDON G
Study: 27967281
Drug: 6.4% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% maltodextrin solution (MAL)
Study: 27967281
Drug: 7.1% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.1% glucose solution (GLU)
Study: 27967281
Drug: Artificially sweetened
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificially sweetened solution (PLA)
Study: 25557776
Drug: Biofeedback training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback training twice daily for 5 days, concurrent with CPM therapy
Study: 23158522
Drug: Everolimus 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 4.5 mg/m² per day (titrated to achieve blood trough concentrations of 5-15 ng/mL)
Study: 22082247
Drug: Redesigning Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Redesigning Daily Occupations program
Study: 19525739
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT) - antidepressants and body‐mind‐spirit group psychotherapy
Study: 19525739
Drug: Monotherapy (MT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (MT) - antidepressants only
Study: 11198056
Drug: Dothiepin 100
Normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin 100 mg
Study: 12173784
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg
Study: 3828485
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered rectally (80 mg)
Study: 3828485
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered orally (80 mg)
Study: 3828485
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered intravenously (2.2 mg)
Study: 31394146
Drug: ARK intervention
Normalized name: Arkaliox
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARK intervention (Antibiotic Review Kit)
Study: 26486868
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator 0.9 mg/kg
Study: 26486868
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatment during the first 24 hours
Study: 14518310
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with 5-FU (1000 mg/m2 continuously over 5d/28d) and Folinic Acid (200 mg/m2 over 15 minutes 5d/28d)
Study: 7912249
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of ursodeoxycholic acid (Group A: 18 patients)
Study: 2574656
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in Crohn's colitis
Study: 2574656
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in ileocolitis
Study: 2574656
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in ileitis
Study: 28286287
Drug: Capecitabine-based treatment
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine-based treatment
Study: 28286287
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in combination with oxaliplatin and bevacizumab
Study: 26251016
Drug: Filgrastim 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 2.5 µg/kg/day for 7 days
Study: 26251016
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 µg/kg/day for 7 days
Study: 26251016
Drug: Filgrastim 10
Normalized name: pegfilgrastim 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 10 µg/kg/day for 5 days
Study: 26251016
Drug: BK0023 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK0023 (all doses)
Study: 3168567
Drug: Methylprednisolone 80
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 80 mg/24 h and aminophylline by continuous infusion (Group A)
Study: 3168567
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline and methylprednisolone 80 mg in two equally divided doses by mouth (Group B)
Study: 17564002
Drug: Dexamethasone, 4
Normalized name: Dexamethasone, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 4 mg i.v.
Study: 17564002
Drug: Ondansetron, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron, 4 mg i.v.
Study: 11522614
Drug: MEN 11420
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN 11420 (8 mg intravenously)
Study: 9632121
Drug: Serum sex
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum sex hormone-binding globulin (SHBG)
Study: 7829401
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus dexamethasone (HDMP+Dx)
Study: 2142700
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg dexamethasone
Study: 30535174
Drug: Parent-implemented communication
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-implemented communication treatment
Study: 27501654
Drug: Dorzolamide-timolol treatment
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol treatment
Study: 24712047
Drug: 600 mL
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mL liquid test meal consumed three times (breakfast, lunch, dinner)
Study: 24712047
Drug: 300 mL
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL liquid test meal consumed six times (breakfast, snack, lunch, snack, dinner, snack)
Study: 24712047
Drug: 600 mL
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mL regimen
Study: 22159169
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (1 g)
Study: 12760313
Drug: Naproxen 1
Normalized name: naproxen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1 g/day
Study: 30187872
Drug: ethinyl oestradiol/cyproterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl oestradiol/cyproterone tablets (Group A)
Study: 30187872
Drug: desogestrel/ethinyl oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: desogestrel/ethinyl oestradiol tablets (Group B)
Study: 30187872
Drug: metformin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (for women with insulin resistance)
Study: 24567309
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral supplementation of multivitamins (B-complex, C and E)
Study: 14606378
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 400 micrograms/h of alfentanil with 50 mg/h of lidocaine (group T-AL)
Study: 14606378
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 400 micrograms/h of alfentanil (group T-A)
Study: 14606378
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 400 micrograms/h of alfentanil (group L-A)
Study: 2675854
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release oral salbutamol (8 mg)
Study: 26253869
Drug: S‐1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 (40 mg/m² twice per day) for 2 consecutive weeks repeated every 3 weeks for 1 year
Study: 26253869
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) (60 mg/m²) on day 1 plus oral S‐1 (40 mg/m² twice per day) for 2 consecutive weeks repeated every 3 weeks for four cycles
Study: 22173149
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration (8:00 to 10:00 a.m.)
Study: 22173149
Drug: Afternoon administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon administration (1:00 to 3:00 p.m.)
Study: 21381157
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care ERP (3 sessions over 6 weeks of low-intensity counseling with ERP bibliotherapy, followed by therapist-administered ERP if needed)
Study: 21381157
Drug: Standard ERP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ERP (therapist-administered ERP with no lower-intensity lead-in)
Study: 8343314
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg)
Study: 10838018
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous administration of ivabradine
Study: 10838018
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose oral administration of ivabradine every 12 hours
Study: 9178278
Drug: Glutamine-containing parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine-containing parenteral nutrition (PN)
Study: 9178278
Drug: Control parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control parenteral nutrition (isonitrogenous, isoenergetic)
Study: 22386043
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 5 ppm for up to 28 days
Study: 15807716
Drug: NFV 625
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFV 625 mg (1250 mg bid)
Study: 15807716
Drug: NFV 625
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFV 625 mg
Study: 15807716
Drug: NFV 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFV 250 mg
Study: 12364482
Drug: Somatostatin (SRIF-14)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SRIF-14) 2.0 micro g/kg/h i.v. over 120 min
Study: 12364482
Drug: Cortistatin (CST-14)
Normalized name: hydrogenated poly(C6-14 olefin; 2 CST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortistatin (CST-14) 2.0 micro g/kg/h i.v. over 120 min
Study: 10591454
Drug: Surgical treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment, uvulopalatopharyngoplasty
Study: 1931746
Drug: 2% Remodent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Remodent and 0.2% NaF solutions
Study: 1931746
Drug: 0.2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NaF solutions (Control group)
Study: 31565869
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (SEQ) - refrained from exercise during months 0 to 6, then supervised exercise program during months 7 to 12
Study: 31565869
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (SEQ) - weight change between 6 and 18 months
Study: 26447687
Drug: Combined SPT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined SPT and pregabalin 300 mg daily
Study: 22309472
Drug: Exposure‐only therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure‐only therapy (Ex)
Study: 22309472
Drug: Exposure‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure‐based treatment combined with cognitive restructuring (ExCR)
Study: 17705570
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/day for 6 weeks
Study: 11348602
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/day
Study: 17705570
Drug: Quinapril 40
Normalized name: quinapril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 40 mg/day
Study: 17705570
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/day + HCTZ 12.5 mg/day
Study: 11552924
Drug: 1-week regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-week regimen with ranitidine bismuth citrate 400 mg b.d. for 7 days
Study: 11552924
Drug: 2-week regimen
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week regimen with ranitidine bismuth citrate 400 mg b.d. for 14 days
Study: 11552924
Drug: 4-week regimen
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week regimen with ranitidine bismuth citrate 400 mg b.d. for 28 days
Study: 3144443
Drug: 0.3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg.kg‐1 nalbuphine intravenously
Study: 3144443
Drug: 0.1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg‐1 nalbuphine
Study: 3144443
Drug: 0.3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg.kg‐1 nalbuphine
Study: 27412799
Drug: Taurine (3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (3 g per day)
Study: 27412799
Drug: Magnesium (340 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (340 mg per day)
Study: 27412799
Drug: Taurine (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (3% solution) and/or high-Mg diet (600 mg per 100 g)
Study: 22615543
Drug: Combination ART
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ART in pregnancy
Study: 14505263
Drug: GnRH-Agonist induced
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-Agonist induced reversible ovarian suppression
Study: 1677266
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of alprazolam
Study: 29392283
Drug: Pathogen-reduced platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogen-reduced platelets in additive solution
Study: 29392283
Drug: Platelets in
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets in additive solution
Study: 29392283
Drug: Pathogen-reduced platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogen-reduced platelets in additive solution vs platelets in plasma
Study: 29392283
Drug: Pathogen-reduced platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogen-reduced platelets in additive solution vs platelets in additive solution
Study: 26712560
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab monthly for 6 months
Study: 26712560
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab monthly for 6 months
Study: 19284121
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg/kg of ideal weight)
Study: 19284121
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg/kg of real weight)
Study: 19284121
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg/kg of ideal weight)
Study: 19284121
Drug: Rocuronium (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.6 mg/kg of real weight)
Study: 17873530
Drug: Albendazole (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (as preoperative adjuvant therapy)
Study: 17873530
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with albendazole and PAIR
Study: 15692217
Drug: Iron saccharate
Normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron saccharate complex (ISC), 100 mg twice weekly for 2 months and once weekly thereafter
Study: 15692217
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (SFGC), 62.5 mg twice weekly for 2 months and once weekly thereafter
Study: 12667322
Drug: Pituitrin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pituitrin infusion (2 U/min) during gastroduodenal artery blockage
Study: 12667322
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (10 ml at 4 ml/min) as control
Study: 9707191
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL HS‐HES
Study: 9707191
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g mannitol
Study: 7661873
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/g)
Study: 7661873
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg/day)
Study: 7661873
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pravastatin and Gemfibrozil (40 + 1200 mg/day)
Study: 31704740
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly
Study: 31704740
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKAs) with target INR 2‐3
Study: 23812272
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion of 2 mg/kgBW/h
Study: 20151997
Drug: Doubling atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling atorvastatin to 80 mg
Study: 16491133
Drug: Reboxetine plus
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine plus 400 mg celecoxib for 6 weeks
Study: 11007240
Drug: Immunosuppressive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drug therapy (glucocorticoids, cyclosporin, FK 506)
Study: 1523353
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg tid during 12 weeks
Study: 6498567
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Same as Group I with addition of fentanyl (2 micrograms X kg‐1) before skin incision and 1/8 of the initial dose every 15 minutes during surgery
Study: 6498567
Drug: Group IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV: Same as Group I with additional infusion of lidocaine (30 micrograms X kg‐1 X min‐1)
Study: 6498567
Drug: Group V:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group V: 0.65 MAC of nitrous oxide and fentanyl (7.5 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Study: 6498567
Drug: Group VI:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group VI: 0.65 MAC of nitrous oxide and fentanyl (15 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Study: 7561435
Drug: Cefoxitin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin prophylaxis (2 g intravenously, n = 25)
Study: 31412242
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1 g per day for 21 days
Study: 28978802
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever live‐attenuated vaccine (YFLAV)
Study: 23761087
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.70 mg
Study: 20168099
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 2 x 5 mg (5 mg intravenously at randomization and at month 12)
Study: 20168099
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 1 x 5 mg (5 mg intravenously at randomization and placebo at month 12)
Study: 17935572
Drug: Daily infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infant probiotic supplement for the first 6 months of life
Study: 15453623
Drug: Topical benzydamine
Normalized name: benzydamine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzydamine hydrochloride 3% cream
Study: 9389780
Drug: Oestradiol gel
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol gel (1.0 mg of oestradiol daily, Divigel/Sandrena)
Study: 9389780
Drug: Oestradiol delivering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol delivering patch (50 micrograms oestradiol/24 h, Estraderm TTS)
Study: 29618017
Drug: Monthly practice
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly practice for 6 months
Study: 26365335
Drug: S05985 (perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: S05985 (perindopril 5 mg and amlodipine 5 mg)
Study: 26365335
Drug: Perindopril tert‐butylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril tert‐butylamine 4 mg
Study: 24216317
Drug: Atorvastatin preloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin preloading (80 mg 12 h and 40 mg 2 h pre-PCI)
Study: 24216317
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (atorvastatin 40 mg/day)
Study: 24216317
Drug: Atorvastatin preloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin preloading